Latest Insights

XtalPi and PharmaEngine Get Approvals for Phase I Trial of AI-Designed PRMT5 Inhibitor

XtalPi and PharmaEngine have received clearance from regulators in Taiwan and Australia to begin first-in-human testing of PEP08, an AI-designed second-generation PRMT5 inhibitor targeting solid tumors. The milestone also triggered …

Continue ›››

Oracle, AMD and Absci Collaborate to Scale AI-Driven Drug Discovery

Absci has entered a collaboration with Oracle and AMD to expand the performance and scale of its AI-based drug discovery platform. The agreement is centered on Oracle Cloud Infrastructure (OCI) …

Continue ›››

Biotech in Space: Microgravity, Ventures, and the Path to Production

From public labs to private stations, the near-term outlook for orbital bioprocessing and its first commercial pipelines The renewed surge in space ambition extends beyond rockets and habitats by driving …

Continue ›››

GE HealthCare to Acquire icometrix for AI-Powered Brain MRI Solutions

GE HealthCare has entered into an agreement to acquire icometrix, a Belgium-based company specializing in AI-driven brain imaging analysis for neurological disorders including Alzheimer’s disease. The deal is intended to …

Continue ›››

Eli Lilly Offers Access to AI Models Trained on $1B Worth of Proprietary Drug Discovery Data

In a rare move for the pharmaceutical industry, Eli Lilly and Company has launched TuneLab, a platform that gives external biotech companies access to its proprietary AI models for drug …

Continue ›››

Eli Lilly Partners with insitro on Machine Learning Models for Small Molecule Discovery

insitro has entered a new collaboration with Eli Lilly to develop machine learning models capable of predicting pharmacological properties of small molecules, including their in vivo behavior. The models will …

Continue ›››

Integra Therapeutics Raises €10.7 Million to Advance Gene Writing Platform and CAR-T Validation

Integra Therapeutics has closed a €10.7 million pre-Series A investment round to accelerate development of its FiCAT gene writing platform and preclinical validation of CAR-T therapies. The financing was led …

Continue ›››

Proscia Launches New AI Pathology Platform to Link Patients With Drug Trials

Proscia, headquartered in Philadelphia, has introduced Aperture, a pathology-based AI system that links diagnostic laboratories with biopharmaceutical companies to accelerate precision medicine. The platform is designed to identify eligible patients …

Continue ›››

XtalPi and PharmaEngine Get Approvals for Phase I Trial of AI-Designed PRMT5 Inhibitor

Oracle, AMD and Absci Collaborate to Scale AI-Driven Drug Discovery

Biotech in Space: Microgravity, Ventures, and the Path to Production

GE HealthCare to Acquire icometrix for AI-Powered Brain MRI Solutions

Eli Lilly Offers Access to AI Models Trained on $1B Worth of Proprietary Drug Discovery Data

Eli Lilly Partners with insitro on Machine Learning Models for Small Molecule Discovery

Integra Therapeutics Raises €10.7 Million to Advance Gene Writing Platform and CAR-T Validation

Proscia Launches New AI Pathology Platform to Link Patients With Drug Trials

Digital Twins in Rare Diseases: From Virtual Trials to Personalized Care

Consensus and Biomni Integrate Agentic AI into Biomedical Literature Research

LatchBio Publishes 25-Million-Cell Open-Source Spatial Transcriptomics Atlas

Ketryx Gets $39 Million to Expand AI Compliance Infrastructure for Life Sciences